Investigation of the effect of PD-L1 blockade on triple negative breast cancer cells using fourier transform infrared spectroscopy

Mohamed H.M. Ali, Salman M. Toor, Fazle Rakib, Raghvendra Mall, Ehsan Ullah, Kamal Mroue, Prasanna R. Kolatkar, Khalid Al-Saad, Eyad Elkord

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Interactions between programmed death-1 (PD-1) with its ligand PD-L1 on tumor cells can antagonize T cell responses. Inhibiting these interactions using immune checkpoint inhibitors has shown promise in cancer immunotherapy. MDA-MB-231 is a triple negative breast cancer cell line that expresses PD-L1. In this study, we investigated the biochemical changes in MDA-MB-231 cells following treatment with atezolizumab, a specific PD-L1 blocker. Our readouts were Fourier Transform Infrared (FTIR) spectroscopy and flow cytometric analyses. Chemometrical analysis, such as principal component analysis (PCA), was applied to delineate the spectral differences. We were able to identify the chemical alterations in both protein and lipid structure of the treated cells. We found that there was a shift from random coil and α-helical structure to β-sheet conformation of PD-L1 on tumor cells due to atezolizumab treatment, which could hinder binding with its receptors on immune cells, ensuring sustained T cell activation for potent immune responses. This work provides novel information about the effects of atezolizumab at molecular and cellular levels. FTIR bio-spectroscopy, in combination with chemometric analyses, may expedite research and offer new approaches for cancer immunology.

Original languageEnglish
Article number109
JournalVaccines
Volume7
Issue number3
DOIs
Publication statusPublished - Sep 2019

Fingerprint

Triple Negative Breast Neoplasms
Fourier Transform Infrared Spectroscopy
Neoplasms
T-Lymphocytes
Allergy and Immunology
Principal Component Analysis
Immunotherapy
Ligands
Lipids
Cell Line
Therapeutics
Research
MPDL3280A
Proteins

Keywords

  • Biochemical alterations
  • Breast cancer
  • Chemometric analysis
  • FTIR
  • Spectroscopy
  • Tumor cells

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Investigation of the effect of PD-L1 blockade on triple negative breast cancer cells using fourier transform infrared spectroscopy. / Ali, Mohamed H.M.; Toor, Salman M.; Rakib, Fazle; Mall, Raghvendra; Ullah, Ehsan; Mroue, Kamal; Kolatkar, Prasanna R.; Al-Saad, Khalid; Elkord, Eyad.

In: Vaccines, Vol. 7, No. 3, 109, 09.2019.

Research output: Contribution to journalArticle

Ali, Mohamed H.M. ; Toor, Salman M. ; Rakib, Fazle ; Mall, Raghvendra ; Ullah, Ehsan ; Mroue, Kamal ; Kolatkar, Prasanna R. ; Al-Saad, Khalid ; Elkord, Eyad. / Investigation of the effect of PD-L1 blockade on triple negative breast cancer cells using fourier transform infrared spectroscopy. In: Vaccines. 2019 ; Vol. 7, No. 3.
@article{bb333b7c3b4546c488241f21bfc2f5e2,
title = "Investigation of the effect of PD-L1 blockade on triple negative breast cancer cells using fourier transform infrared spectroscopy",
abstract = "Interactions between programmed death-1 (PD-1) with its ligand PD-L1 on tumor cells can antagonize T cell responses. Inhibiting these interactions using immune checkpoint inhibitors has shown promise in cancer immunotherapy. MDA-MB-231 is a triple negative breast cancer cell line that expresses PD-L1. In this study, we investigated the biochemical changes in MDA-MB-231 cells following treatment with atezolizumab, a specific PD-L1 blocker. Our readouts were Fourier Transform Infrared (FTIR) spectroscopy and flow cytometric analyses. Chemometrical analysis, such as principal component analysis (PCA), was applied to delineate the spectral differences. We were able to identify the chemical alterations in both protein and lipid structure of the treated cells. We found that there was a shift from random coil and α-helical structure to β-sheet conformation of PD-L1 on tumor cells due to atezolizumab treatment, which could hinder binding with its receptors on immune cells, ensuring sustained T cell activation for potent immune responses. This work provides novel information about the effects of atezolizumab at molecular and cellular levels. FTIR bio-spectroscopy, in combination with chemometric analyses, may expedite research and offer new approaches for cancer immunology.",
keywords = "Biochemical alterations, Breast cancer, Chemometric analysis, FTIR, Spectroscopy, Tumor cells",
author = "Ali, {Mohamed H.M.} and Toor, {Salman M.} and Fazle Rakib and Raghvendra Mall and Ehsan Ullah and Kamal Mroue and Kolatkar, {Prasanna R.} and Khalid Al-Saad and Eyad Elkord",
year = "2019",
month = "9",
doi = "10.3390/vaccines7030109",
language = "English",
volume = "7",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Investigation of the effect of PD-L1 blockade on triple negative breast cancer cells using fourier transform infrared spectroscopy

AU - Ali, Mohamed H.M.

AU - Toor, Salman M.

AU - Rakib, Fazle

AU - Mall, Raghvendra

AU - Ullah, Ehsan

AU - Mroue, Kamal

AU - Kolatkar, Prasanna R.

AU - Al-Saad, Khalid

AU - Elkord, Eyad

PY - 2019/9

Y1 - 2019/9

N2 - Interactions between programmed death-1 (PD-1) with its ligand PD-L1 on tumor cells can antagonize T cell responses. Inhibiting these interactions using immune checkpoint inhibitors has shown promise in cancer immunotherapy. MDA-MB-231 is a triple negative breast cancer cell line that expresses PD-L1. In this study, we investigated the biochemical changes in MDA-MB-231 cells following treatment with atezolizumab, a specific PD-L1 blocker. Our readouts were Fourier Transform Infrared (FTIR) spectroscopy and flow cytometric analyses. Chemometrical analysis, such as principal component analysis (PCA), was applied to delineate the spectral differences. We were able to identify the chemical alterations in both protein and lipid structure of the treated cells. We found that there was a shift from random coil and α-helical structure to β-sheet conformation of PD-L1 on tumor cells due to atezolizumab treatment, which could hinder binding with its receptors on immune cells, ensuring sustained T cell activation for potent immune responses. This work provides novel information about the effects of atezolizumab at molecular and cellular levels. FTIR bio-spectroscopy, in combination with chemometric analyses, may expedite research and offer new approaches for cancer immunology.

AB - Interactions between programmed death-1 (PD-1) with its ligand PD-L1 on tumor cells can antagonize T cell responses. Inhibiting these interactions using immune checkpoint inhibitors has shown promise in cancer immunotherapy. MDA-MB-231 is a triple negative breast cancer cell line that expresses PD-L1. In this study, we investigated the biochemical changes in MDA-MB-231 cells following treatment with atezolizumab, a specific PD-L1 blocker. Our readouts were Fourier Transform Infrared (FTIR) spectroscopy and flow cytometric analyses. Chemometrical analysis, such as principal component analysis (PCA), was applied to delineate the spectral differences. We were able to identify the chemical alterations in both protein and lipid structure of the treated cells. We found that there was a shift from random coil and α-helical structure to β-sheet conformation of PD-L1 on tumor cells due to atezolizumab treatment, which could hinder binding with its receptors on immune cells, ensuring sustained T cell activation for potent immune responses. This work provides novel information about the effects of atezolizumab at molecular and cellular levels. FTIR bio-spectroscopy, in combination with chemometric analyses, may expedite research and offer new approaches for cancer immunology.

KW - Biochemical alterations

KW - Breast cancer

KW - Chemometric analysis

KW - FTIR

KW - Spectroscopy

KW - Tumor cells

UR - http://www.scopus.com/inward/record.url?scp=85070580711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070580711&partnerID=8YFLogxK

U2 - 10.3390/vaccines7030109

DO - 10.3390/vaccines7030109

M3 - Article

AN - SCOPUS:85070580711

VL - 7

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 3

M1 - 109

ER -